SA
CAH

Nasdaq, Russell 2000 below the 200-day average · S&P 500 below the 50-day average (VIX 22.3)

Overview →

Cardinal Health is a $223B revenue pharmaceutical and medical products distributor operating one of the largest pharmaceutical distribution networks in the U.S., serving 90% of hospitals and 60,000+ pharmacies. The company operates two segments: Pharmaceutical (90%+ of revenue) distributing branded/generic drugs with razor-thin 2-3% gross margins, and Medical (remainder) distributing surgical supplies, gloves, and at-home medical products with higher 15-20% margins but smaller scale.

HealthcareHealthcare Distribution & Pharmaceutical Wholesalinglow - This is a scale business with high fixed costs in distribution infrastructure, but pricing is largely pass-through with minimal ability to expand margins. Volume growth translates to modest profit growth due to thin margins. Generic drug launches provide temporary margin expansion opportunities (6-12 months of exclusivity pricing), but competition quickly compresses spreads. Operating leverage exists in Medical segment where incremental sales flow through at higher margins.

Business Overview

01Pharmaceutical Distribution (~90% of revenue): Wholesale distribution of branded and generic drugs to retail pharmacies, hospitals, and alternate care sites
02Medical Segment (~10% of revenue): Distribution of medical-surgical products, PPE, Cardinal Health-branded products, and specialty pharmaceutical distribution
03Specialty pharmaceutical services: Oncology, rare disease distribution with higher-touch services and better margins

Cardinal operates a high-volume, low-margin distribution model with 3.7% gross margins and 1.0% operating margins. Profitability depends on operational efficiency, inventory turns (12-15x annually), and scale advantages in logistics. The pharmaceutical segment earns distribution fees from manufacturers (typically $5-15 per prescription) plus spread on generic drugs where Cardinal can negotiate volume discounts. Medical segment generates higher margins (15-20% gross) through private-label Cardinal Health branded products and value-added services. Competitive advantage stems from $10B+ invested infrastructure including 50+ distribution centers with sophisticated cold-chain capabilities, proprietary pharmacy management software, and long-term contracts with major pharmacy chains (CVS, Walgreens) and hospital systems.

What Moves the Stock

Generic drug launch calendar and exclusivity windows - major launches can add $50-150M in annual profit during exclusivity periods

Pharmaceutical pricing dynamics and manufacturer fee negotiations - 50-100bps margin compression/expansion materially impacts $200B+ revenue base

Opioid litigation settlements and reserve adequacy - company faces $6.4B in settlement obligations through 2038

Medical segment growth and Cardinal Health branded product penetration - higher margin business growing mid-single digits

Specialty pharmaceutical growth in oncology and rare disease - 15-20% margins vs. 2-3% in traditional pharma distribution

Hospital utilization trends and elective procedure volumes - drives Medical segment demand for surgical supplies

Watch on Earnings
Pharmaceutical segment profit dollars (not margin %) - absolute profit matters more than percentage on massive revenue baseGeneric drug program performance and number of exclusivity launchesMedical segment organic revenue growth and operating margin expansionFree cash flow generation and debt paydown progress - company targeting $2B+ annual FCFCustomer retention rates with large chain pharmacy and hospital customers

Risk Factors

Amazon Pharmacy and vertical integration by PBMs/payers - Amazon's entry into pharmacy distribution and potential for CVS/Walgreens to self-distribute could disintermediate wholesalers

Continued pharmaceutical margin compression - manufacturer direct-to-pharmacy models and increased generic competition erode distribution economics

Regulatory risk from drug pricing legislation - potential government price controls or importation policies could disrupt distribution economics and fee structures

Oligopoly competition with McKesson and AmerenSourceBergen - three players control 90%+ market share, leading to intense price competition for large customer contracts

Customer consolidation reducing negotiating leverage - mega-mergers among pharmacy chains and hospital systems increase buyer power and pressure distribution fees

Negative equity position (-$19.3 P/B) due to $6.4B opioid litigation settlement obligations and share repurchases - company has structural negative net worth

High leverage with -3.34 Debt/Equity and $15B+ gross debt - refinancing risk if credit markets tighten, though investment-grade rating provides access to capital

Current ratio of 0.91 indicates working capital pressure - business model requires continuous access to short-term financing for inventory

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - Pharmaceutical demand is non-discretionary and driven by demographics, chronic disease prevalence, and prescription volumes rather than GDP. Medical segment has moderate cyclicality tied to elective procedures and hospital capital spending, but represents only 10% of business. Recession may slightly reduce elective surgeries but increase generic drug utilization as patients trade down from branded drugs.

Interest Rates

Rising rates create moderate headwind through two channels: (1) $15B+ debt load increases interest expense by $150M per 100bps rate increase, and (2) working capital financing costs rise as company finances 30-60 day inventory and receivables cycles. However, pharmaceutical distribution contracts often include inflation/cost pass-through provisions. Higher rates also compress valuation multiples for low-growth, high-leverage distributors.

Credit

Moderate exposure to healthcare provider credit quality. Cardinal extends 30-60 day payment terms to hospital systems and independent pharmacies. Rural hospital closures and independent pharmacy bankruptcies create bad debt risk, though large chain customers (CVS, Walgreens) represent majority of revenue with minimal credit risk. Tightening credit conditions reduce independent pharmacy formation and consolidate market toward large chains.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

value - Stock trades at 0.2x sales and 18x EBITDA with 3.6% FCF yield, attracting deep value investors willing to look past negative book value. Recent 74% one-year return suggests momentum investors have entered. Dividend yield around 2% attracts some income investors, though payout constrained by opioid settlement obligations. Not a growth story given -1.9% revenue decline and mature market position.

moderate - Healthcare distribution is defensive with stable demand, but stock experiences volatility around earnings due to generic launch timing, opioid litigation developments, and large customer contract renewals. Beta likely 0.8-1.0 range. Recent 48.7% six-month return shows elevated volatility as market reprices opioid settlement risk and improved generic economics.

Key Metrics to Watch
Generic drug launch pipeline and exclusivity calendar from FDA Orange Book
Hospital admissions and elective surgery volumes (AHA statistics) - drives Medical segment demand
Independent pharmacy formation/closure rates - impacts customer base stability
Pharmaceutical manufacturer fee agreements and rebate structures
Opioid settlement payment schedule adherence and reserve adequacy
Working capital days and cash conversion cycle efficiency
Market share in specialty pharmaceutical distribution (oncology, rare disease)
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.